Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

144.74
-2.7600-1.87%
Post-market: 144.910.1700+0.12%19:58 EDT
Volume:5.04M
Turnover:731.35M
Market Cap:179.58B
PE:-55.35
High:148.00
Open:147.65
Low:144.00
Close:147.50
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.99
T/O Rate:0.41%
Dividend:3.22
Dividend Rate:2.22%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.18
PE(LYR):21.35

Loading ...

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

Moderna Inc. Stock Rallies 5.4%, Outperforms Peers

Dow Jones
·
Sep 12

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

TIPRANKS
·
Sep 11

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Sep 09

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Sep 09

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Sep 09

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS
·
Sep 09

Movement Alert|Gilead Sciences Falls 3.18% in Regular Trading, Trading at $148.555

Market Focus
·
Sep 08

Movement Alert|Gilead Sciences Falls 3.47% in Pre-Market Trading, Trading at $146.39

Market Focus
·
Sep 08

Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026

Reuters
·
Sep 08

Gilead Sciences (GILD) Receives a Buy from Bernstein

TIPRANKS
·
Sep 08

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 04

Gilead’s Arcus-Backed Cancer Trial Reaches Completion, Setting Up a Key Immuno-Oncology Catalyst

TIPRANKS
·
Sep 04

Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer

Reuters
·
Sep 03

Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares

Reuters
·
Sep 03